Intermediate-onset colorectal cancer: A clinical and familial boundary between both early and late-onset colorectal cancer.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 17 02 2019
accepted: 23 04 2019
entrez: 17 5 2019
pubmed: 17 5 2019
medline: 14 1 2020
Statut: epublish

Résumé

Comparative studies of colorectal cancer (CRC) according to the age of onset have found differences between early-onset CRC (EOCRC) and late-onset CRC (LOCRC). Using this as a starting point, we wished to determine whether intermediate-onset CRC (IOCRC) might also be considered as an independent group within CRC. We performed a retrospective comparative study of the clinicopathological and familial features, as well as of the symptoms and their duration, of a total of 272 subjects diagnosed with CRC classified into three groups according to the age-of-onset (98 EOCRC, 83 IOCRC and 91 LOCRC). The results show that from a clinicopathological point of view, IOCRC shared certain features with EOCRC (gender, prognosis), and with LOCRC (multiple primary CRCs), whereas it also had characteristics that were specific for IOCRC (mean number of associated polyps). A gradual progression was observed from EOCRC to LOCRC from a greater family aggregation to sporadic cases, in parallel with a change of Lynch Syndrome cases to the sporadic microsatellite instability pathway, with the IOCRC being a boundary group that is more related to EOCRC. With respect to symptoms, duration and correlation with stages, IOCRC appeared more similar to EOCRC. Clinically, IOCRC behaves as a transitional group between EOCRC and LOCRC, with features in common with both groups, but also with IOCRC-specific features. Excluding cases with familial cancer history, the awareness for EOCRC diagnosis should be extended to IOCRC.

Identifiants

pubmed: 31095598
doi: 10.1371/journal.pone.0216472
pii: PONE-D-19-04698
pmc: PMC6521992
doi:

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0216472

Subventions

Organisme : NCI NIH HHS
ID : R01 CA202797
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA184792
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA187956
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072851
Pays : United States

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

PLoS One. 2013 Nov 21;8(11):e80015
pubmed: 24278232
Cancer Res. 1998 Aug 1;58(15):3455-60
pubmed: 9699680
Ann Surg Oncol. 2012 Sep;19(9):2814-21
pubmed: 22476818
Oncogene. 2002 May 9;21(20):3253-7
pubmed: 12082642
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Cancer Res. 1997 Mar 1;57(5):808-11
pubmed: 9041175
Clin Colorectal Cancer. 2017 Mar;16(1):31-37
pubmed: 27600984
Histopathology. 2013 Nov;63(5):603-15
pubmed: 23991632
Ann Surg Oncol. 2011 Nov;18(12):3285-91
pubmed: 21590452
Nat Rev Cancer. 2004 Dec;4(12):988-93
pubmed: 15573120
J Mol Diagn. 2014 Jan;16(1):116-26
pubmed: 24184227
Clin Transl Oncol. 2014 Dec;16(12):1072-8
pubmed: 25358801
Colorectal Dis. 2009 Jul;11(6):601-8
pubmed: 18637931
Mol Cancer. 2010 May 06;9:100
pubmed: 20459617
Clin Gastroenterol Hepatol. 2017 May;15(5):728-737.e3
pubmed: 27856366
Eur J Cancer. 2012 Mar;48(4):501-9
pubmed: 22226571
World J Gastroenterol. 2010 Aug 7;16(29):3697-703
pubmed: 20677343
PLoS One. 2012;7(9):e45357
pubmed: 23049789
PLoS One. 2014 Aug 01;9(8):e103159
pubmed: 25083765
Gastroenterology. 2004 Nov;127(5):1578-88
pubmed: 15521024
PLoS One. 2010 Nov 12;5(11):e13978
pubmed: 21103049
Mol Carcinog. 2016 May;55(5):705-16
pubmed: 25808986

Auteurs

María Arriba (M)

Department of Clinical Biochemistry, "Gregorio Marañón" University Hospital, Madrid, Spain.

Carmen Sánchez (C)

Department of Surgery, "12 de Octubre" University Hospital, Madrid, Spain.

Alfredo Vivas (A)

Department of Surgery, "12 de Octubre" University Hospital, Madrid, Spain.

O A Nutu (OA)

Department of Surgery, "12 de Octubre" University Hospital, Madrid, Spain.

Daniel Rueda (D)

Molecular Biology Laboratory, "12 de Octubre" University Hospital, Madrid, Spain.
Centre for Biomedical Research of "12 de Octubre" University Hospital, Madrid, Spain.

Sandra Tapial (S)

Centre for Biomedical Research of "12 de Octubre" University Hospital, Madrid, Spain.

Yolanda Rodríguez (Y)

Department of Pathology, "12 de Octubre" University Hospital, Madrid, Spain.

Lorena Brandáriz (L)

Department of Surgery, "Fundación Jiménez Díaz" University Hospital, Madrid, Spain.
Health Research Institute, "Fundación Jiménez Díaz" University Hospital, Madrid, Spain.

Juan L García (JL)

Molecular Medicine Unit, Department of Medicine, Institute of Molecular and Cellular Biology of Cancer (IBMCC) and Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca-SACYL-CSIC, Salamanca, Spain.

Damián García-Olmo (D)

Department of Surgery, "Fundación Jiménez Díaz" University Hospital, Madrid, Spain.
Health Research Institute, "Fundación Jiménez Díaz" University Hospital, Madrid, Spain.

Ajay Goel (A)

Center for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute, Charles A, Sammons Cancer Center, Baylor University Medical Center, Dallas, Texas, United States of America.

Rogelio González-Sarmiento (R)

Molecular Medicine Unit, Department of Medicine, Institute of Molecular and Cellular Biology of Cancer (IBMCC) and Biomedical Research Institute of Salamanca (IBSAL), University of Salamanca-SACYL-CSIC, Salamanca, Spain.

Miguel Urioste (M)

Centre for Biomedical Network Research on Rare Diseases (CIBERER), Institute of Health Carlos III, Madrid, Spain.
Familial Cancer Clinical Unit, Spanish National Cancer Centre (CNIO), Madrid, Spain.

José Perea (J)

Department of Surgery, "Fundación Jiménez Díaz" University Hospital, Madrid, Spain.
Health Research Institute, "Fundación Jiménez Díaz" University Hospital, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH